A comparison of volume‐reduced versus standard HLA/HPA–matched apheresis platelets in alloimmunized adult patients

Abstract

VR-APs showed lower 1- and 24-hour CCIs than standard-APs, which can be largely explained by the lower PLT dose of VR-APs. The benefits of plasma reduction should seriously be outweighed given these lower increments.